IBC 2024 | SMM & MGUS: clinical relevance, the PROMISE study & the role of genomics
In this discussion, Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, and Elizabeth O’Donnell, MD, Massachusetts General Hospital, Boston, MA, discuss the importance of detecting and risk stratifying patients with smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS), sharing insights into the PROMISE study (NCT03689595). Dr Maura and Dr O’Donnell then go on to debate the role of genomics, challenges with currently available data, and the need to improve clinical trial design for these individuals. This session was filmed at IBC 2024, held in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
